{"id":198934,"name":"AVANIR PHARMACEUTICALS","slug":"avanir-pharmaceuticals","state":"CA","country":"United States of America","description":"","totalSpending":410000,"filings":7,"yearlySpending":[{"year":2021,"income":140000},{"year":2022,"income":270000}],"issues":[{"code":"HCR","display":"Health Issues"},{"code":"MED","display":"Medical/Disease Research/Clinical Labs"},{"code":"VET","display":"Veterans"},{"code":"MMM","display":"Medicare/Medicaid"},{"code":"BUD","display":"Budget/Appropriations"}],"firms":["AVANIR PHARMACEUTICALS"],"lobbyists":["CATHERINE FERGUSON"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE"],"sampleDescriptions":["Pharmaceutical Research and Development, Post-Acute Care Reform, Central Nervous System Disorders, Patent Reform, FDA Reform, FDA Approval Pathways, Medicare/Medicaid.","Pharmaceutical Research and Development, Post-Acute Care Reform, Central Nervous System Disorders, Patent Reform, FDA Reform, FDA Approval Pathways, Medicare/Medicaid.","Pharmaceutical Research and Development, Post-Acute Care Reform, Central Nervous System Disorders, Patent Reform, FDA Reform, FDA Approval Pathways, Medicare/Medicaid.","Pharmaceutical Research and Development, Post-Acute Care Reform, Central Nervous System Disorders, Patent Reform, FDA Reform, FDA Approval Pathways, Medicare/Medicaid.","Pharmaceutical Research and Development, Post-Acute Care Reform, Central Nervous System Disorders, Patent Reform, FDA Reform, FDA Approval Pathways, Medicare/Medicaid."]}